This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH et al. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant 2008; 41: 935–940.
Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008; 14: 672–684.
Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220–228.
Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055–3060.
Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477–485.
Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010; 45: 249–253.
McCune JS, Gibbs JP, Slattery JT . Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155–165.
Yang LP, Keam SJ, Keating GM . Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 2007; 67: 2211–2230.
Stumpf JL . Deferasirox. Am J Health Syst Pharm 2007; 64: 606–616.
Majhail NS, Lazarus HM, Burns LJ . Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41: 997–1003.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sweiss, K., Patel, P. & Rondelli, D. Deferasirox increases BU blood concentrations. Bone Marrow Transplant 47, 315–316 (2012). https://doi.org/10.1038/bmt.2011.75
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.75
This article is cited by
-
Clinical Pharmacology of Deferasirox
Clinical Pharmacokinetics (2014)